UBS Maintains Buy on Legend Biotech, Lowers Price Target to $48

Benzinga · 1d ago
UBS analyst Ashwani Verma maintains Legend Biotech (NASDAQ:LEGN) with a Buy and lowers the price target from $54 to $48.